HRP20200253T1 - Benzoimidazol-2-il pirimidinski modulatori histaminskog h4 receptora - Google Patents
Benzoimidazol-2-il pirimidinski modulatori histaminskog h4 receptora Download PDFInfo
- Publication number
- HRP20200253T1 HRP20200253T1 HRP20200253TT HRP20200253T HRP20200253T1 HR P20200253 T1 HRP20200253 T1 HR P20200253T1 HR P20200253T T HRP20200253T T HR P20200253TT HR P20200253 T HRP20200253 T HR P20200253T HR P20200253 T1 HRP20200253 T1 HR P20200253T1
- Authority
- HR
- Croatia
- Prior art keywords
- disease
- autoimmune
- image
- pruritus
- hemitartrate tetrahydrate
- Prior art date
Links
- 102000004187 Histamine H4 receptors Human genes 0.000 title claims 3
- 108090000796 Histamine H4 receptors Proteins 0.000 title claims 3
- WTZRQYJHRXQWTK-UHFFFAOYSA-N 2-pyrimidin-2-yl-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1C1=NC=CC=N1 WTZRQYJHRXQWTK-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 24
- 208000003251 Pruritus Diseases 0.000 claims 16
- JJXABLRAISJPTN-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid octahydrate Chemical compound O.O.O.O.O.O.O.O.OC(C(O)C(O)=O)C(O)=O JJXABLRAISJPTN-UHFFFAOYSA-N 0.000 claims 14
- 208000035475 disorder Diseases 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 10
- 208000006673 asthma Diseases 0.000 claims 6
- 239000012535 impurity Substances 0.000 claims 6
- -1 Hemitartrate tetrahydrate [5-(4,6-Dimethyl-1H-benzoimidazol-2-yl)-4-methyl-pyrimidin-2-yl]-[3-(1-methyl-piperidin-4-yl)-propyl ]-amine Chemical compound 0.000 claims 5
- 238000002441 X-ray diffraction Methods 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 208000026935 allergic disease Diseases 0.000 claims 4
- 230000007815 allergy Effects 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 208000020576 Adrenal disease Diseases 0.000 claims 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 2
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 206010008635 Cholestasis Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000001840 Dandruff Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010012442 Dermatitis contact Diseases 0.000 claims 2
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 2
- 206010013774 Dry eye Diseases 0.000 claims 2
- 206010015943 Eye inflammation Diseases 0.000 claims 2
- 206010017533 Fungal infection Diseases 0.000 claims 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 201000002980 Hyperparathyroidism Diseases 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 2
- 206010022971 Iron Deficiencies Diseases 0.000 claims 2
- 206010023126 Jaundice Diseases 0.000 claims 2
- 208000018501 Lymphatic disease Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000031888 Mycoses Diseases 0.000 claims 2
- 208000000592 Nasal Polyps Diseases 0.000 claims 2
- 206010052437 Nasal discomfort Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000030852 Parasitic disease Diseases 0.000 claims 2
- 201000011152 Pemphigus Diseases 0.000 claims 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims 2
- 208000008601 Polycythemia Diseases 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000003699 Punctate palmoplantar keratoderma Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 206010039509 Scab Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000006045 Spondylarthropathies Diseases 0.000 claims 2
- 206010042496 Sunburn Diseases 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 208000024799 Thyroid disease Diseases 0.000 claims 2
- 241000159241 Toxicodendron Species 0.000 claims 2
- 241000159243 Toxicodendron radicans Species 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 206010048222 Xerosis Diseases 0.000 claims 2
- 230000000172 allergic effect Effects 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 2
- 201000004339 autoimmune neuropathy Diseases 0.000 claims 2
- 208000006424 autoimmune oophoritis Diseases 0.000 claims 2
- 208000010928 autoimmune thyroid disease Diseases 0.000 claims 2
- 201000004982 autoimmune uveitis Diseases 0.000 claims 2
- 231100000359 cholestasis Toxicity 0.000 claims 2
- 230000007870 cholestasis Effects 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 238000000502 dialysis Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000014617 hemorrhoid Diseases 0.000 claims 2
- 208000002557 hidradenitis Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 208000018555 lymphatic system disease Diseases 0.000 claims 2
- 230000036210 malignancy Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 201000005737 orchitis Diseases 0.000 claims 2
- 230000003071 parasitic effect Effects 0.000 claims 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 2
- 208000005987 polymyositis Diseases 0.000 claims 2
- 230000035935 pregnancy Effects 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000037390 scarring Effects 0.000 claims 2
- 201000005671 spondyloarthropathy Diseases 0.000 claims 2
- 206010043207 temporal arteritis Diseases 0.000 claims 2
- 208000021510 thyroid gland disease Diseases 0.000 claims 2
- 201000006082 Chickenpox Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010046980 Varicella Diseases 0.000 claims 1
- 241000700647 Variola virus Species 0.000 claims 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/08—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by cooling of the solution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Materials Engineering (AREA)
- Metallurgy (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Claims (13)
1. Hemitartarat tetrahidrat [5-(4,6-Dimetil-1H-benzoimidazol-2-il)-4-metil-pirimidin-2-il]-[3-(1-metil-piperidin-4-il)-propil]-amina formule:
[image]
2. Hemitartarat tetrahidrat prema zahtjevu 1, gdje profil difrakcije X-zraka spomenutog hemitartarat tetrahidrata obuhvaća sljedeće signale :
[image]
3. Hemitartarat tetrahidrat prema zahtjevu 1, gdje profil difrakcije X-zraka spomenutog hemitartarat tetrahidrata obuhvaća sljedeće signale :
[image]
4. Hemitartarat tetrahidrat prema zahtjevu 1, gdje profil difrakcije X-zraka spomenutog hemitartarat tetrahidrata obuhvaća sljedeće signale :
[image]
(nastavak)
[image]
5. Hemitartarat tetrahidrat prema zahtjevu 1, gdje profil difrakcije X-zraka spomenutog hemitartarat tetrahidrata obuhvaća sljedeće signale:
[image]
6. Hemitartarat tetrahidrat prema zahtjevu 1, gdje profil difrakcije X-zraka spomenutog hemitartarat tetrahidrata obuhvaća sljedeće signale :
[image]
(nastavak)
[image]
7. Hemitartarat tetrahidrat [5-(4,6-Dimetil-1H-benzoimidazol-2-il)-4-metil-pirimidin-2-il]-[3-(1-metil-piperidin-4-il)-propil]-amina formule:
[image]
gdje spomenuti hemitartarat tetrahidrat je suštinski bez nečistoća I1, I3 i I8 formula:
[image]
gdje izraz "suštinski bez" označava da nečistoća ne može biti otkrivena korištenjem visokoefikasne tekuće kromatografije (HPLC) kao detektorom s masenim spektrometrom (MS) ili ultra-ljubičastim spektroskopom (UV), nalaženjem jedne ili više masa nečistoća, relativnih vremena retencije i količine (kao postotka relativne površine).
8. Hemitartarat tetrahidrat [5-(4,6-Dimetil-1H-benzoimidazol-2-il)-4-metil-pirimidin-2-il]-[3-(1-metil-piperidin-4-il)-propil]-amina prema zahtjevu 7, gdje je spomenuti hemitartarat tetrahidrat dalje suštinski slobodan bar od nečistoće I5 formule:
[image]
9. Hemitartarat tetrahidrat [5-(4,6-Dimetil-1H-benzoimidazol-2-il)-4-metil-pirimidin-2-il]-[3-(1-metil-piperidin-4-il)-propil]-amina prema zahtjevu 8, gdje spomenuti hemitartarat tetrahidrat ne sadrži više od oko 0.2% nečistoće I7 formule:
[image]
10. Hemitartarat tetrahidrat [5-(4,6-dimetil-1H-benzoimidazol-2-il)-4-metil-pirimidin-2-il]-[3-(1-metil-piperidin-4-il)-propil]-amina prema zahtjevu 9, gdje spomenuti hemitartarat tetrahidrat ne sadrži više od oko 0.06% nečistoće I7 formule:
[image]
11. Farmaceutski sastav za upotrebu u liječenju bolesti, poremećaja ili medicinskog stanja u kojem posreduje aktivnost receptora histamina H4 , koji sadrži efikasnu količinu bar spoja prema bilo kojem od zahtjeva 1 ili 7 do 10, gdje bolest, poremećaj, ili medicinsko stanje je upala,
ili gdje bolest, poremećaj ili medicinsko stanje je izabrano iz grupe koju čine: upalni poremećaji, alergijski poremećaji, dermatološki poremećaji, autoimuna bolest, limfatični poremećaji i imunodeficijentni poremećaji,
ili gdje bolest, poremećaj ili medicinsko stanje je izabrano između: alergije, astme, autoimunih bolesti i pruritusa,
ili gdje spomenuta upalna bolest je jedna od kolitisa, Crohnove bolesti i ulceroznog kolitisa,
ili gdje je bolest, poremećaj ili medicinsko stanje izabrano između : alergije, astme, eozinofilne astme, suhog oka, kronične opstruktivne bolesti pluća (COPD), ateroskleroze, reumatoidnog artritisa, multipla skleroze, upalnih bolesti crijeva, psorijaze, pruritusa, svrbeža kože, atopijskog dermatitisa, urtikarije, očne upale, konjuktivitisa, nazalnih polipa, alergijskog rinitisa, nazalnog svrbeža, parazitskih ili gljivičnih infekcija, gnojnog hidradenitisa, maligniteta, kao što su limfomi, žutice, policitemije, punktatne palmoplantarne keratoderme, bolesti štitnjače/hiperparatiroidizam, dijabetesa, vodenih kozica, anemije uslijed nedostatka željeza, psihijatrijskih bolesti, lijekovima izazvanog svrbeža; kolestaze; svrbeža u trudnoći, kseroze, opekotina od sunca, peruti, krasta/ožiljaka, ugriza od insekata, otrovnog bršljana, otrovnog hrasta, hemoroida, kontaktnog dermatitisa, svrbeža u vezi s godinama, svrbeža u vezi s dijalizom, skleroderme, autoimunih bolesti štitnjače, imuno-posredovane šećerne bolesti, lupusa, mijastenije gravis, autoimunih neuropatija, autoimunog uveitisa, autoimune hemolitičke anemije, perniciozne anemije, autoimune trombocitopenije, temporalnog arteritisa, anti-fosfolipidnog sindroma, vaskulitida, Behcetove bolesti, herpetiformnog dermatitisa, pemfigus vulgarisa, vitiliga, primarne bilijarne ciroze, autoimunog hepatitisa, autoimunog ooforitisa i orhitisa, autoimune bolesti nadbubrežne žlijezde, polimiozitisa, dermatomiozitisa, spondiloartropatije, Sjogrenovog sindroma i pruritusa.
12. Spoj prema bilo kojem od zahtjeva 1-10 za upotrebu u terapiji.
13. Spoj prema zahtjevu 1 za upotrebu u postupku liječenja subjekta koji pati od ili kod kojeg je dijagnosticirana bolest, poremećaj ili medicinsko stanje u kojem posreduje aktivnost receptora histamina H4, gdje postupak obuhvaća davanje subjektu kojem je potrebno takvo liječenje efikasne količine spoja prema zahtjevu 1,
gdje bolest, poremećaj ili medicinsko stanje je upala,
ili gdje bolest, poremećaj ili medicinsko stanje je izabrano iz grupe koju čine: upalni poremećaji, alergijski poremećaji, dermatološki poremećaji, autoimuna bolest, limfatični poremećaji i imunodeficijentni poremećaji ,
ili gdje bolest, poremećaj ili medicinsko stanje je izabrano između: alergije, astme, autoimunih bolesti, i pruritusa,
ili gdje spomenuta upalna bolest crijeva je jedna od kolitisa, Crohnove bolesti i ulceroznog kolitisa,
ili gdje bolest, poremećaj, ili medicinsko stanje je izabrano između: alergije, astme, eozinofilne astme, suhog oka, kronične opstruktivne bolesti pluća (COPD), ateroskleroze, reumatoidnog artritisa, multipla skleroze, upalnih bolesti crijeva, psorijaze, pruritusa, svrbeža kože, atopijskog dermatitisa, urtikarije, očne upale, konjuktivitisa, nazalnih polipa, alergijskog rinitisa, nazalnog svrbeža, parazitskih i gljivičnih infekcija, gnojnog hidradenitisa, maligniteta, kao što su limfomi, žutica, policitemija, punktatne palmoplantarne keratoderme, bolesti štitnjače/hiperparatiroidizma, dijabetesa, vodene kozice, anemije uslijed nedostatka željeza, psihijatrijskih bolesti, svrbeža izazvanog lijekovima; kolestaze; svrbeža u trudnoći, kseroze, opekotina od sunca, peruti, krasta/ožiljaka, ugriza insekata, otrovnog bršljana, otrovnog hrasta, hemoroida, kontaktnog dermatitisa, svrbeža u vezi s godinama, svrbeža u vezi s dijalizom, skleroderme, autoimunih bolesti štitnjače, imuno-posredovane šećerne bolesti, lupusa, mijastenije gravis, autoimunih neuropatija, autoimunog uveitisa, autoimune hemolitičke anemije, perniciozne anemije, autoimune trombocitopenije, temporalnog arteritisa, anti-fosfolipidnog sindroma, vaskulitida, Behcetove bolesti, herpetiformnog dermatitisa, pemfigus vulgarisa, vitiliga, primarne bilijarne ciroze, autoimunog hepatitisa, autoimunog ooforitisa i orhitisa, autoimune bolesti nadbubrežne žlijezde, polimiozitisa, dermatomiozitisa, spondiloartropatije, Sjogrenovog sindroma i pruritusa.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361773706P | 2013-03-06 | 2013-03-06 | |
US201361776260P | 2013-03-11 | 2013-03-11 | |
US201361784909P | 2013-03-14 | 2013-03-14 | |
EP14760540.6A EP2964229B1 (en) | 2013-03-06 | 2014-03-06 | Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor |
PCT/US2014/021130 WO2014138368A1 (en) | 2013-03-06 | 2014-03-06 | Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200253T1 true HRP20200253T1 (hr) | 2020-05-29 |
Family
ID=51488591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200253TT HRP20200253T1 (hr) | 2013-03-06 | 2020-02-14 | Benzoimidazol-2-il pirimidinski modulatori histaminskog h4 receptora |
Country Status (38)
Country | Link |
---|---|
US (4) | US8859575B2 (hr) |
EP (2) | EP2964229B1 (hr) |
JP (1) | JP6471103B2 (hr) |
KR (1) | KR102230383B1 (hr) |
CN (1) | CN105025898B (hr) |
AU (1) | AU2014225675B2 (hr) |
BR (1) | BR112015021463A8 (hr) |
CA (1) | CA2903737C (hr) |
CL (1) | CL2015002434A1 (hr) |
CR (1) | CR20150435A (hr) |
CY (1) | CY1122545T1 (hr) |
DK (1) | DK2964229T3 (hr) |
DO (1) | DOP2016000027A (hr) |
EA (1) | EA201591648A1 (hr) |
ES (1) | ES2773543T3 (hr) |
GT (1) | GT201500243A (hr) |
HK (1) | HK1218513A1 (hr) |
HR (1) | HRP20200253T1 (hr) |
HU (1) | HUE047681T2 (hr) |
IL (1) | IL240247B (hr) |
JO (1) | JO3516B1 (hr) |
LT (1) | LT2964229T (hr) |
MX (1) | MX2015011688A (hr) |
MY (1) | MY180726A (hr) |
NZ (1) | NZ710640A (hr) |
PE (1) | PE20151536A1 (hr) |
PH (1) | PH12015501731B1 (hr) |
PL (1) | PL2964229T3 (hr) |
PT (1) | PT2964229T (hr) |
RS (1) | RS59909B1 (hr) |
SA (1) | SA515360981B1 (hr) |
SG (1) | SG11201507117XA (hr) |
SI (1) | SI2964229T1 (hr) |
TW (1) | TWI617554B (hr) |
UA (1) | UA118754C2 (hr) |
UY (1) | UY35370A (hr) |
WO (1) | WO2014138368A1 (hr) |
ZA (1) | ZA201507351B (hr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ571691A (en) | 2006-03-31 | 2011-07-29 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor |
US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
UY35370A (es) | 2013-03-06 | 2014-09-30 | Janssen Pharmaceutica Nv | Moduladores benzoimidazol-2-il pirimidina del receptor de histamina h4 |
JO3773B1 (ar) | 2013-03-14 | 2021-01-31 | Janssen Pharmaceutica Nv | معدلات p2x7 |
JO3509B1 (ar) | 2013-03-14 | 2020-07-05 | Janssen Pharmaceutica Nv | معدلات p2x7 |
JP6294953B2 (ja) | 2013-03-14 | 2018-03-14 | ヤンセン ファーマシューティカ エヌ.ベー. | P2x7調節物質 |
EP2970304B1 (en) | 2013-03-14 | 2018-08-15 | Janssen Pharmaceutica NV | P2x7 modulators |
ES2714048T3 (es) | 2014-09-12 | 2019-05-24 | Janssen Pharmaceutica Nv | Moduladores de P2X7 |
WO2018133139A1 (zh) | 2017-01-21 | 2018-07-26 | 宁波知明生物科技有限公司 | 芍药苷-6'-o-苯磺酸酯在治疗干燥综合征的应用 |
TW202035409A (zh) | 2018-09-28 | 2020-10-01 | 比利時商健生藥品公司 | 單醯基甘油脂肪酶調節劑 |
JP7482116B2 (ja) | 2018-09-28 | 2024-05-13 | ヤンセン ファーマシューティカ エヌ.ベー. | モノアシルグリセロールリパーゼ調節因子 |
KR20220075386A (ko) | 2019-09-30 | 2022-06-08 | 얀센 파마슈티카 엔.브이. | 방사성 표지된 mgl pet 리간드 |
CA3176946A1 (en) | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
Family Cites Families (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3005852A (en) | 1959-12-22 | 1961-10-24 | Gen Aniline & Film Corp | Production of sulfoxides and sulfones |
GB1062357A (en) | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
US3931195A (en) | 1971-03-03 | 1976-01-06 | Mead Johnson & Company | Substituted piperidines |
US4191828A (en) | 1976-04-14 | 1980-03-04 | Richardson-Merrell Inc. | Process for preparing 2-(2,2-dicyclohexylethyl)piperidine |
US4337341A (en) | 1976-11-02 | 1982-06-29 | Eli Lilly And Company | 4a-Aryl-octahydro-1H-2-pyrindines |
US4190601A (en) | 1978-05-31 | 1980-02-26 | Union Carbide Corporation | Production of tertiary amines by reductive alkylation |
JPS6130576A (ja) | 1984-07-24 | 1986-02-12 | Ube Ind Ltd | 2−アミノ−5−シアノピリミジンの製法 |
GB9410031D0 (en) | 1994-05-19 | 1994-07-06 | Merck Sharp & Dohme | Therapeutic agents |
GB9422391D0 (en) | 1994-11-05 | 1995-01-04 | Solvay Interox Ltd | Oxidation of organosulphur compounds |
BR9509985A (pt) | 1995-12-12 | 1998-11-03 | Omeros Med Sys Inc | Solução para irrigação e método para inibição de dor inflamação e esparmo |
WO1997036890A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5880140A (en) | 1996-04-03 | 1999-03-09 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
CA2250936A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5883105A (en) | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5939439A (en) | 1996-12-30 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
AU5495798A (en) | 1997-01-16 | 1998-08-07 | Sekisui Chemical Co., Ltd. | External preparations for percutaneous absorption |
JP2001509176A (ja) | 1997-01-17 | 2001-07-10 | メルク エンド カンパニー インコーポレーテッド | インテグリンアンタゴニスト |
US5945422A (en) | 1997-02-05 | 1999-08-31 | Warner-Lambert Company | N-oxides of amino containing pyrido 2,3-D! pyrimidines |
WO1998044797A1 (en) | 1997-04-07 | 1998-10-15 | Merck & Co., Inc. | A method of treating cancer |
GB9801231D0 (en) | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
US6399612B1 (en) | 1997-10-06 | 2002-06-04 | Warner-Lambert Company | Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
NZ506417A (en) | 1998-02-17 | 2003-05-30 | Tularik Inc | Anti-viral pyrimidine derivatives |
JP4533534B2 (ja) | 1998-06-19 | 2010-09-01 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | グリコーゲンシンターゼキナーゼ3のインヒビター |
SI1038875T1 (en) * | 1999-03-25 | 2003-12-31 | Synthon B.V. | Imidazopyridine derivatives and process for making them |
WO2001000610A1 (de) | 1999-06-23 | 2001-01-04 | Aventis Pharma Deutschland Gmbh | Substituierte benzimidazole |
TWI279402B (en) | 1999-08-20 | 2007-04-21 | Banyu Pharma Co Ltd | Spiro compounds having NPY antagonistic activities and agents containing the same |
WO2001023387A2 (en) | 1999-09-30 | 2001-04-05 | Neurogen Corporation | CERTAIN ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES |
SK13752001A3 (sk) | 1999-12-27 | 2002-07-02 | Japan Tobacco, Inc. | Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv |
DE10006453A1 (de) | 2000-02-14 | 2001-08-16 | Bayer Ag | Piperidylcarbonsäuren als Integrinantagonisten |
CN1592621A (zh) * | 2000-04-24 | 2005-03-09 | 特瓦制药工业有限公司 | 唑吡坦半酒石酸盐 |
PT1473036E (pt) * | 2000-04-24 | 2006-10-31 | Teva Pharma | Solvato de hemitartarato de zolpidem |
AU2001268711A1 (en) | 2000-06-23 | 2002-01-08 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
AU2001289615A1 (en) | 2000-06-28 | 2002-01-08 | Thromb-X N.V. | Pluripotent embryonic stem (es) cell lines, improved methods for their production, and their use for germ line transmission and for the generation of genetically modified animals |
RU2276142C2 (ru) | 2000-07-21 | 2006-05-10 | Зингента Партисипейшнс Аг | Способ получения 4,6-диметокси-2-метилсульфонилпиримидина (варианты) и применение |
AU9502601A (en) | 2000-09-06 | 2002-03-22 | Chiron Corp | Inhibitors of glycogen synthase kinase 3 |
CA2430037A1 (en) | 2000-11-20 | 2002-05-30 | Michael S. South | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
US20030130264A1 (en) | 2001-02-16 | 2003-07-10 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
AU2002336273A1 (en) | 2001-03-09 | 2002-09-24 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic compounds and their use as histamine h4 ligands. |
AU2002247402A1 (en) | 2001-03-23 | 2002-10-08 | Chugai Seiyaku Kabushiki Kaisha | Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis |
JP2004525150A (ja) | 2001-03-30 | 2004-08-19 | スミスクライン ビーチャム コーポレーション | 治療用化合物としてのピラゾロピリジン類の使用 |
DE60229059D1 (de) | 2001-05-08 | 2008-11-06 | Univ Yale | Proteomimetische verbindungen und verfahren |
AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
HUP0401747A3 (en) | 2001-11-05 | 2005-06-28 | Merck Patent Gmbh | Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
US7148236B2 (en) | 2002-01-17 | 2006-12-12 | Merck & Co., Inc. | Modulators of acetylcholine receptors |
TWI270542B (en) | 2002-02-07 | 2007-01-11 | Sumitomo Chemical Co | Method for preparing sulfone or sulfoxide compound |
US7314937B2 (en) | 2002-03-21 | 2008-01-01 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses |
WO2004012736A1 (en) | 2002-08-02 | 2004-02-12 | Genesoft Pharmaceuticals, Inc. | Biaryl compounds having anti-infective activity |
WO2004022061A1 (en) | 2002-09-06 | 2004-03-18 | Janssen Pharmaceutica, N.V. | Use of indolyl derivatives for the manufacture of a medicament for the treatment allergic rhinitis |
ATE325125T1 (de) | 2002-09-06 | 2006-06-15 | Janssen Pharmaceutica Nv | Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden |
US20040127395A1 (en) | 2002-09-06 | 2004-07-01 | Desai Pragnya J. | Use of histamine H4 receptor modulators for the treatment of allergy and asthma |
CN1694704A (zh) | 2002-09-06 | 2005-11-09 | 詹森药业有限公司 | (1h-苯并咪唑-2-基)-(哌嗪基)-甲酮衍生物及其相关化合物作为组胺h4受体拮抗剂用于治疗炎性和过敏性疾病 |
US7405221B2 (en) | 2002-09-27 | 2008-07-29 | Merck & Co., Inc. | Substituted pyrimidines |
TW200501960A (en) | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
US20040105856A1 (en) | 2002-12-02 | 2004-06-03 | Robin Thurmond | Use of histamine H4 receptor antagonist for the treatment of inflammatory responses |
CA2523261C (en) | 2003-05-05 | 2009-07-07 | F. Hoffmann-La Roche Ag | Fused pyrimidine derivatives with crf activity |
US7244739B2 (en) | 2003-05-14 | 2007-07-17 | Torreypines Therapeutics, Inc. | Compounds and uses thereof in modulating amyloid beta |
SE0302116D0 (sv) | 2003-07-21 | 2003-07-21 | Astrazeneca Ab | Novel compounds |
CA2528805A1 (en) | 2003-08-13 | 2005-05-06 | Chiron Corporation | Gsk-3 inhibitors and uses thereof |
KR101127201B1 (ko) | 2003-09-22 | 2012-04-12 | 에스*바이오 피티이 리미티드 | 벤즈이미다졸 유도체와 그의 제조방법 및 약학적 적용 |
EP1670774A1 (en) | 2003-09-30 | 2006-06-21 | Janssen Pharmaceutica N.V. | Quinoxaline compounds |
RU2006110561A (ru) | 2003-09-30 | 2007-10-10 | Янссен Фармацевтика Н.В. (Be) | Соединения бензоимидазола |
EP1670739A4 (en) | 2003-10-08 | 2007-08-08 | Bristol Myers Squibb Co | CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS |
EP1679309A4 (en) | 2003-10-24 | 2007-03-28 | Ono Pharmaceutical Co | ANTISTRESS MEDICAMENT AND ITS MEDICAL USE |
US8277831B2 (en) | 2004-02-17 | 2012-10-02 | Advanced Technologies And Regenerative Medicine, Llc. | Drug-enhanced adhesion prevention |
CA2560896C (en) | 2004-03-25 | 2013-06-18 | Janssen Pharmaceutica, N.V. | Imidazole compounds |
CN1960977B (zh) | 2004-05-31 | 2010-07-21 | 万有制药株式会社 | 喹唑啉衍生物 |
EP1824832B1 (en) | 2004-06-30 | 2011-04-27 | Janssen Pharmaceutica NV | Aryl-substituted benzimidazole and imidazopyridine ethers as anti-cancer agents |
CN101048406B (zh) | 2004-08-31 | 2010-12-22 | 万有制药株式会社 | 新型取代的咪唑衍生物 |
WO2006042102A2 (en) | 2004-10-05 | 2006-04-20 | Neurogen Corporation | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
US7381732B2 (en) | 2004-10-26 | 2008-06-03 | Bristol-Myers Squibb Company | Pyrazolobenzamides and derivatives as factor Xa inhibitors |
WO2006063466A1 (en) | 2004-12-17 | 2006-06-22 | Merck Frosst Canada Ltd. | 2-(phenyl or heterocyclic)-1h-phenantrho[9,10-d]imidazoles as mpges-1 inhibitors |
US7442716B2 (en) | 2004-12-17 | 2008-10-28 | Merck Frosst Canada Ltd. | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors |
CA2602583A1 (en) | 2005-03-24 | 2006-09-28 | Janssen Pharmaceutica N.V. | Biaryl derived amide modulators of vanilloid vr1 receptor |
WO2007044085A2 (en) | 2005-05-19 | 2007-04-19 | Xenon Pharmaceuticals Inc. | Heteroaryl compounds and their uses as therapeutic agents |
KR101354114B1 (ko) | 2005-06-14 | 2014-01-24 | 타이젠 바이오테크놀러지 컴퍼니 리미티드 | 피리미딘 화합물 |
US8193206B2 (en) | 2005-06-14 | 2012-06-05 | Taigen Biotechnology Co., Ltd. | Pyrimidine compounds |
ES2375929T3 (es) | 2005-07-04 | 2012-03-07 | High Point Pharmaceuticals, Llc | Antagonistas del receptor histamina h3. |
US20090306038A1 (en) | 2005-09-13 | 2009-12-10 | Carceller Gonzalez Elena | 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity |
AR056560A1 (es) | 2005-10-06 | 2007-10-10 | Astrazeneca Ab | Pirrolopiridinonas como moduladores cb1 |
WO2007070173A2 (en) | 2005-10-31 | 2007-06-21 | Merck & Co., Inc. | Cetp inhibitors |
WO2007063935A1 (ja) | 2005-12-02 | 2007-06-07 | Mitsubishi Tanabe Pharma Corporation | 芳香族化合物 |
WO2007095753A1 (en) | 2006-02-24 | 2007-08-30 | Merck Frosst Canada Ltd. | 2-(phenyl or heterocyclic) - 1h-phenanthro [9,10-d] imidazoles |
NZ571691A (en) * | 2006-03-31 | 2011-07-29 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor |
AU2007235577B2 (en) | 2006-03-31 | 2011-09-15 | Janssen Pharmaceutica N.V. | Benzoimidazol-2-yl pyridines as modulators of the histamine H4 receptor |
WO2007117401A2 (en) | 2006-04-07 | 2007-10-18 | Janssen Pharmaceutica N.V. | Indoles and benzoimidazoles as modulators of the histamine h4 receptor |
US20090069343A1 (en) | 2006-04-10 | 2009-03-12 | Dunford Paul J | Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus |
US20090192158A1 (en) | 2006-05-02 | 2009-07-30 | Stacia Kargman | Methods for Treating or Preventing Neoplasias |
AU2007252249A1 (en) | 2006-05-18 | 2007-11-29 | Merck Frosst Canada Ltd. | Phenanthrene derivatives as mPGES-1 inhibitors |
KR20090028819A (ko) | 2006-07-11 | 2009-03-19 | 얀센 파마슈티카 엔.브이. | 히스타민 h4 수용체의 벤조푸로- 및 벤조티에노피리미딘 조절제 |
US8779154B2 (en) * | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
CL2008000467A1 (es) | 2007-02-14 | 2008-08-22 | Janssen Pharmaceutica Nv | Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma |
WO2009068512A1 (en) | 2007-11-30 | 2009-06-04 | Palau Pharma, S. A. | 2 -amino-pyrimidine derivatives as histamine h4 antagonists |
WO2009079001A1 (en) | 2007-12-18 | 2009-06-25 | Janssen Pharmaceutica N.V. | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine h4 receptor |
BRPI0915720A2 (pt) | 2008-06-12 | 2015-08-04 | Janssen Pharmaceutica Nv | Moduladores de diaminopiridina, pirimidina, e piridazina do receptor de histamina h4 |
BRPI0915526A2 (pt) | 2008-06-12 | 2016-01-26 | Janssen Pharmaceutica Nv | uso de um antagonista da histamina h4 para o tratamento de aderências pós-operatórias |
PE20140592A1 (es) | 2008-06-30 | 2014-05-16 | Janssen Pharmaceutica Nv | Proceso para la preparacion de derivados de benzoimidazol-2-il pirimidina |
MX2011000080A (es) | 2008-06-30 | 2011-03-02 | Janssen Pharmaceutica Nv | Proceso para la preparacion de derivados de pirimidina sustituidos. |
US8852569B2 (en) | 2008-08-28 | 2014-10-07 | The General Hospital Corporation | Prevention and treatment of itch with cysteine protease inhibition |
IT1395963B1 (it) * | 2009-06-04 | 2012-11-02 | Rottapharm Spa | Forme cristalline di 6-(1h-imidazol-1-il)-2-fenil chinazolina e dei suoi sali |
TWI519533B (zh) | 2010-11-01 | 2016-02-01 | Lg生命科學有限公司 | 1-{(2S)-2-胺基-4-[2,4-雙(三氟甲基)-5,8-二氫吡啶并[3,4-d]嘧啶-7(6H)-基]-4-側氧丁基}-5,5-二氟哌啶-2-酮酒石酸鹽之水合物 |
EP2465498A1 (en) * | 2010-11-23 | 2012-06-20 | Faes Farma, S.A. | Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions |
UY35370A (es) | 2013-03-06 | 2014-09-30 | Janssen Pharmaceutica Nv | Moduladores benzoimidazol-2-il pirimidina del receptor de histamina h4 |
-
2014
- 2014-03-06 UY UY0001035370A patent/UY35370A/es unknown
- 2014-03-06 MX MX2015011688A patent/MX2015011688A/es active IP Right Grant
- 2014-03-06 PL PL14760540T patent/PL2964229T3/pl unknown
- 2014-03-06 PE PE2015001832A patent/PE20151536A1/es not_active Application Discontinuation
- 2014-03-06 PT PT147605406T patent/PT2964229T/pt unknown
- 2014-03-06 BR BR112015021463A patent/BR112015021463A8/pt not_active Application Discontinuation
- 2014-03-06 HU HUE14760540A patent/HUE047681T2/hu unknown
- 2014-03-06 EA EA201591648A patent/EA201591648A1/ru unknown
- 2014-03-06 EP EP14760540.6A patent/EP2964229B1/en active Active
- 2014-03-06 JO JOP/2014/0074A patent/JO3516B1/ar active
- 2014-03-06 KR KR1020157026804A patent/KR102230383B1/ko active IP Right Grant
- 2014-03-06 MY MYPI2015702907A patent/MY180726A/en unknown
- 2014-03-06 CN CN201480012369.2A patent/CN105025898B/zh not_active Expired - Fee Related
- 2014-03-06 US US14/199,634 patent/US8859575B2/en active Active
- 2014-03-06 CA CA2903737A patent/CA2903737C/en active Active
- 2014-03-06 LT LTEP14760540.6T patent/LT2964229T/lt unknown
- 2014-03-06 JP JP2015561646A patent/JP6471103B2/ja not_active Expired - Fee Related
- 2014-03-06 NZ NZ710640A patent/NZ710640A/en not_active IP Right Cessation
- 2014-03-06 SG SG11201507117XA patent/SG11201507117XA/en unknown
- 2014-03-06 ES ES14760540T patent/ES2773543T3/es active Active
- 2014-03-06 SI SI201431440T patent/SI2964229T1/sl unknown
- 2014-03-06 WO PCT/US2014/021130 patent/WO2014138368A1/en active Application Filing
- 2014-03-06 TW TW103107723A patent/TWI617554B/zh not_active IP Right Cessation
- 2014-03-06 RS RS20200160A patent/RS59909B1/sr unknown
- 2014-03-06 EP EP19213615.8A patent/EP3660011A1/en not_active Withdrawn
- 2014-03-06 AU AU2014225675A patent/AU2014225675B2/en not_active Ceased
- 2014-03-06 DK DK14760540.6T patent/DK2964229T3/da active
- 2014-06-03 UA UAA201509634A patent/UA118754C2/uk unknown
- 2014-08-21 US US14/465,677 patent/US9278952B2/en not_active Expired - Fee Related
-
2015
- 2015-07-30 IL IL240247A patent/IL240247B/en active IP Right Grant
- 2015-08-06 PH PH12015501731A patent/PH12015501731B1/en unknown
- 2015-08-24 CR CR20150435A patent/CR20150435A/es unknown
- 2015-08-31 CL CL2015002434A patent/CL2015002434A1/es unknown
- 2015-09-02 GT GT201500243A patent/GT201500243A/es unknown
- 2015-09-03 SA SA515360981A patent/SA515360981B1/ar unknown
- 2015-10-05 ZA ZA2015/07351A patent/ZA201507351B/en unknown
-
2016
- 2016-01-22 DO DO2016000027A patent/DOP2016000027A/es unknown
- 2016-02-18 US US15/047,359 patent/US9434715B2/en active Active
- 2016-06-07 HK HK16106550.1A patent/HK1218513A1/zh unknown
- 2016-08-03 US US15/227,878 patent/US9663497B2/en active Active
-
2020
- 2020-02-03 CY CY20201100085T patent/CY1122545T1/el unknown
- 2020-02-14 HR HRP20200253TT patent/HRP20200253T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200253T1 (hr) | Benzoimidazol-2-il pirimidinski modulatori histaminskog h4 receptora | |
PH12019501098A1 (en) | Pyrrolopyrimidines as cftr potentiators | |
HRP20191919T1 (hr) | Donori nitroksila sa poboljšanim terapijskim indeksom | |
BR112016005881A2 (pt) | composto, composição farmacêutica e uso do composto | |
JP2009532366A5 (hr) | ||
BR112015020998A2 (pt) | compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios | |
UY37328A (es) | Compuestos diazaheterobicíclicos sustituidos y su uso | |
CL2014000122A1 (es) | Compuestos derivados de indazol, inhibidores de janus quinasa (jak); composicion farmaceutica que los comprende; y su uso para tratar rinitis alergica, congestion nasal, asma, bronquitis cronica, artritis, insuficiencia cardiaca, colitis ulcerativa, infeccion viral y bacteriana, cancer y alzheimer, entre otras enfermedades. | |
BR112015015468B8 (pt) | Composto, e, composição farmacêutica | |
CN103027946B (zh) | 一种马钱子总生物碱的提取方法 | |
MX2020011955A (es) | Derivados heterociclicos y uso de los mismos. | |
JP2017505320A5 (hr) | ||
BR112018015851A2 (pt) | composto, e, medicamento. | |
WO2015047982A3 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
BR112016008060A8 (pt) | composto, formulação farmacêutica, processo para preparar um composto de fórmula (i), método para preparação de um composto, uso do composto ou sal farmaceuticamente aceitável do mesmo | |
DOP2010000238A (es) | Farmacoforos duales-antagonistas muscarinicos de pde4 | |
EA201790072A1 (ru) | Производные 2-арил-4-гидрокси-1,3-тиазола для применения в качестве ингибиторов trpm8 в лечении невралгии, болей, хронической обструктивной болезни лёгких и астмы | |
BRPI0414487A (pt) | composto de ácido carboxìlico e composições medicinais contendo os mesmos como o ingrediente ativo | |
Kühn et al. | Impact of dose and dosing frequency of intranasal AZD8848 (a TLR7 agonist) on biomarker response in healthy volunteers | |
PH12016501026A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor | |
EA029678B9 (ru) | Четвертичные соли пиперидиния | |
Wu et al. | A retrospective analysis on 1330 adverse event reports of Qingkailing in China: further perception of its risks and rational use | |
RU2462253C1 (ru) | Способ коррекции нарушения микроциркуляции в плаценте азитромицином при adma-подобной модели гестоза в эксперименте | |
Lin et al. | Vanadium Pentoxide Stimulate Inflammatory Response and Autophagy Via Activating ERK Pathway | |
GT201600072A (es) | Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio |